Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT04167345
- Locations
- 🇮🇪
Royal College of Surgeons in Ireland Clinical Research Centre, Beaumont Hospital, Beaumont, Ireland
🇺🇸The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 176
- Registration Number
- NCT04105972
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel - Campus Jette, Brussels, Belgium
🇧🇪Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
🇦🇺Perth Children's Hospital, Nedlands, Australia
VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)
- Conditions
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT04058210
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 271
- Registration Number
- NCT04058353
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 251
- Registration Number
- NCT04058366
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 458
- Registration Number
- NCT04043806
- Locations
- 🇺🇸
Cystic Fibrosis Institute, Glenview, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 87
- Registration Number
- NCT03912233
- Locations
- 🇳🇱
HagaZiekenhuis van den Haag, Den Haag, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
🇺🇸Tulane Medical Center, New Orleans, Louisiana, United States
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 77
- Registration Number
- NCT03911713
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 115
- Registration Number
- NCT03768089
- Locations
- 🇳🇱
HagaZiekenhuis van den Haag, Den Haag, Netherlands
🇳🇱Academic Medical Center, Amsterdam, Netherlands
🇳🇱UMC St. Radboud, Nijmegen, Netherlands
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 250
- Registration Number
- NCT03764072
- Locations
- 🇺🇸
Lotus Clinical Research, Pasadena, California, United States
🇺🇸Chesapeake Research Group, Pasadena, Maryland, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States